

October 13, 2026

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
--	--

Dear Sir / Madam,

Sub: Q2 & H1 FY27 Earnings Conference Call Invite

Please find enclosed the Q2 & H1 FY27 Earnings conference call invite for the call scheduled on October 29, 2026 at 05.00 PM (IST).

This is for your information and records.

Thanking you,

Yours faithfully,

For Laurus Labs Limited

VENKATESW
AR REDDY
GOGIREDDY

Digitally signed by
VENKATESWAR REDDY
GOGIREDDY
Date: 2026.10.13
15:19:55 +05'30'

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E, Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Laurus Labs Q2 & H1 FY27 Results Conference Call

29 October 2026 at 5:00pm IST

Hyderabad, October 13, 2026: Laurus Labs Ltd (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company will organize a conference call to discuss Q2 & H1 FY27 results followed by an interactive Q&A. The call will be hosted by DAM Capital Advisors. Dial In and other details given below

Date and Time	Thursday, October 29, 2026 - 5:00 pm IST
Conference dial-in	
Primary Number	+91 22 6280 1384
Secondary Number	+91 22 7115 8285 <i>Available all over India</i>
Singapore	+8001012045
Hong Kong	+800964448
USA	+18667462133
UK	+08081011573
Diamond Pass	Event Link

END

Investors Relations Vivek Kumar T +91 40 3980 4366 investorrelations@lauruslabs.com	Media Relations Karthik C T +91 40 3980 4380 mediarelations@lauruslabs.com
---	---

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India
T +91 40 6659 4333, 2342 0500/501 **F** +91 40 6659 4320

Registered Office

Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, **T** +91 891 682 1101, 1102, **F** +91 891 682 1103, E info@lauruslabs.com, **W** lauruslabs.com

About Laurus Labs

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including Anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. During FY2026 Laurus generated ₹ 6,813 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on [LinkedIn](#) | [Twitter](#) | [Facebook](#) | [Instagram](#)